Insmed Inc

1INSM

Company Profile

  • Business description

    Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

  • Contact

    700 US Highway 202/206
    BridgewaterNJ08807
    USA

    T: +1 908 977-9900

    E: [email protected]

    https://www.insmed.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    1,664

Stocks News & Analysis

stocks

ASX miner weathers the storm with strong commodity prices

Lower volumes due cyclone activity but revenues hold steady.
stocks

Eli Lilly earnings: Mounjaro/Zepbound’s massive volume growth more than counters price pressure

We’ve raised our fair value estimate of Lilly stock.
stocks

OpenAI missed multiple revenue targets - here’s why it likely won’t IPO this year

Plus, whichever AI company IPOs first defines what “good” looks like.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,954.7021.20-0.24%
CAC 408,114.840.000.00%
DAX 4024,292.38337.821.41%
Dow JONES (US)49,652.14790.331.62%
FTSE 10010,317.9160.91-0.59%
HKSE25,776.53335.31-1.28%
NASDAQ24,892.31219.070.89%
Nikkei 22559,513.12228.200.38%
NZX 50 Index13,039.20135.891.05%
S&P 5007,209.0173.061.02%
S&P/ASX 2008,729.8021.20-0.24%
SSE Composite Index4,112.164.650.11%

Market Movers